AU772451B2 - Modified exosomes and uses - Google Patents
Modified exosomes and uses Download PDFInfo
- Publication number
- AU772451B2 AU772451B2 AU10514/00A AU1051400A AU772451B2 AU 772451 B2 AU772451 B2 AU 772451B2 AU 10514/00 A AU10514/00 A AU 10514/00A AU 1051400 A AU1051400 A AU 1051400A AU 772451 B2 AU772451 B2 AU 772451B2
- Authority
- AU
- Australia
- Prior art keywords
- molecule
- exosomes
- cells
- mhc
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000001808 exosome Anatomy 0.000 title claims description 265
- 210000004027 cell Anatomy 0.000 claims description 261
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 102
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 102
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 86
- 238000000034 method Methods 0.000 claims description 60
- 239000012528 membrane Substances 0.000 claims description 57
- 210000003630 histaminocyte Anatomy 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 55
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 45
- 108020003175 receptors Proteins 0.000 claims description 44
- 150000007523 nucleic acids Chemical class 0.000 claims description 43
- 108020004707 nucleic acids Proteins 0.000 claims description 42
- 102000039446 nucleic acids Human genes 0.000 claims description 42
- 102000004169 proteins and genes Human genes 0.000 claims description 42
- 238000004519 manufacturing process Methods 0.000 claims description 39
- 239000011324 bead Substances 0.000 claims description 36
- 239000000427 antigen Substances 0.000 claims description 30
- 239000003446 ligand Substances 0.000 claims description 30
- 108091007433 antigens Proteins 0.000 claims description 29
- 102000036639 antigens Human genes 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 238000001514 detection method Methods 0.000 claims description 27
- 239000004816 latex Substances 0.000 claims description 24
- 229920000126 latex Polymers 0.000 claims description 24
- 239000012472 biological sample Substances 0.000 claims description 23
- 230000000890 antigenic effect Effects 0.000 claims description 20
- 230000000638 stimulation Effects 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 17
- 230000028327 secretion Effects 0.000 claims description 17
- 238000002372 labelling Methods 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 15
- 238000000746 purification Methods 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 13
- 230000001086 cytosolic effect Effects 0.000 claims description 12
- 108010028930 invariant chain Proteins 0.000 claims description 12
- 239000000700 radioactive tracer Substances 0.000 claims description 12
- 230000004044 response Effects 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 230000036039 immunity Effects 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 230000004927 fusion Effects 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 7
- 230000003321 amplification Effects 0.000 claims description 7
- 238000002649 immunization Methods 0.000 claims description 7
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 7
- 239000000523 sample Substances 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 6
- 238000011084 recovery Methods 0.000 claims description 6
- 208000016557 Acute basophilic leukemia Diseases 0.000 claims description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 5
- 231100000433 cytotoxic Toxicity 0.000 claims description 4
- 230000001472 cytotoxic effect Effects 0.000 claims description 4
- 230000000144 pharmacologic effect Effects 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 description 35
- 238000000684 flow cytometry Methods 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 21
- 239000005090 green fluorescent protein Substances 0.000 description 20
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 19
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 19
- 210000004698 lymphocyte Anatomy 0.000 description 19
- 239000002609 medium Substances 0.000 description 18
- 239000013598 vector Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- 238000012546 transfer Methods 0.000 description 14
- 102100025222 CD63 antigen Human genes 0.000 description 13
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 13
- 102000054766 genetic haplotypes Human genes 0.000 description 13
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 12
- 239000012894 fetal calf serum Substances 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- 238000001262 western blot Methods 0.000 description 11
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 10
- 241001529936 Murinae Species 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 230000002068 genetic effect Effects 0.000 description 10
- 230000003834 intracellular effect Effects 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 238000012512 characterization method Methods 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 238000012737 microarray-based gene expression Methods 0.000 description 8
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 8
- 108010093013 HLA-DR1 Antigen Proteins 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000001173 tumoral effect Effects 0.000 description 7
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 6
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 108010052285 Membrane Proteins Proteins 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 241000283074 Equus asinus Species 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 238000004624 confocal microscopy Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 238000005199 ultracentrifugation Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 4
- -1 Lampi Proteins 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000028023 exocytosis Effects 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000009738 saturating Methods 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 3
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 3
- 101150117895 LAMP2 gene Proteins 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000035160 transmembrane proteins Human genes 0.000 description 3
- 108091005703 transmembrane proteins Proteins 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102100027221 CD81 antigen Human genes 0.000 description 2
- 102100037904 CD9 antigen Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 2
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 108010038305 down-regulator of transcription 1 Proteins 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000002998 immunogenetic effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100020948 Growth hormone receptor Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000716481 Homo sapiens Lysosome membrane protein 2 Proteins 0.000 description 1
- 101000880098 Homo sapiens Sushi repeat-containing protein SRPX Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102100020983 Lysosome membrane protein 2 Human genes 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 102000005591 NIMA-Interacting Peptidylprolyl Isomerase Human genes 0.000 description 1
- 108010059419 NIMA-Interacting Peptidylprolyl Isomerase Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010068542 Somatotropin Receptors Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 102000056615 human SRPX Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- SYXUBXTYGFJFEH-UHFFFAOYSA-N oat triterpenoid saponin Chemical compound CNC1=CC=CC=C1C(=O)OC1C(C=O)(C)CC2C3(C(O3)CC3C4(CCC5C(C)(CO)C(OC6C(C(O)C(OC7C(C(O)C(O)C(CO)O7)O)CO6)OC6C(C(O)C(O)C(CO)O6)O)CCC53C)C)C4(C)CC(O)C2(C)C1 SYXUBXTYGFJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000006016 thyroid dysfunction Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/5432—Liposomes or microcapsules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR98/13946 | 1998-11-05 | ||
| FR9813946A FR2785543B1 (fr) | 1998-11-05 | 1998-11-05 | Exosomes modifies et utilisations |
| PCT/FR1999/002691 WO2000028001A1 (fr) | 1998-11-05 | 1999-11-04 | Exosomes modifies et utilisations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004203482A Division AU2004203482A1 (en) | 1998-11-05 | 2004-07-29 | Modified exosomes and uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU1051400A AU1051400A (en) | 2000-05-29 |
| AU772451B2 true AU772451B2 (en) | 2004-04-29 |
Family
ID=9532412
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU10514/00A Ceased AU772451B2 (en) | 1998-11-05 | 1999-11-04 | Modified exosomes and uses |
| AU2004203482A Withdrawn AU2004203482A1 (en) | 1998-11-05 | 2004-07-29 | Modified exosomes and uses |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004203482A Withdrawn AU2004203482A1 (en) | 1998-11-05 | 2004-07-29 | Modified exosomes and uses |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1127110A1 (zh) |
| JP (1) | JP2002529074A (zh) |
| CN (1) | CN1325441A (zh) |
| AU (2) | AU772451B2 (zh) |
| CA (1) | CA2349679A1 (zh) |
| EA (1) | EA004428B1 (zh) |
| FR (1) | FR2785543B1 (zh) |
| IL (1) | IL142634A0 (zh) |
| TW (1) | TWI224138B (zh) |
| WO (1) | WO2000028001A1 (zh) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040241176A1 (en) * | 2000-04-27 | 2004-12-02 | Ap Cells. Inc. | Method of producing membrane vesicles |
| ATE512982T1 (de) | 2001-08-17 | 2011-07-15 | Exothera L L C | Verfahren und zusammensetzung zum gezielten einbringen in exosome |
| KR100519384B1 (ko) * | 2002-08-13 | 2005-10-06 | (주)누백스 | 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도 |
| CN1313151C (zh) * | 2002-11-04 | 2007-05-02 | 杭州浙大康泰生物技术有限公司 | 一种新型高效非细胞性疫苗的制备及其用途 |
| JP4939926B2 (ja) | 2003-02-14 | 2012-05-30 | アノシス・インコーポレーテッド | 抗体を生成し抗体レパートリーをスクリーニングするための方法とコンパウンド |
| WO2005094571A1 (ja) * | 2004-03-31 | 2005-10-13 | Japan Science And Technology Agency | 遺伝子改変ヘテロ動物及び該動物を用いたエキソサイトシスの計測方法 |
| WO2006089572A1 (en) * | 2005-02-28 | 2006-08-31 | Charité - Universitätsmedizin Berlin | Polyelectrolyte capsules for detecting antigen-antibody-reactions |
| CN1322115C (zh) * | 2005-07-06 | 2007-06-20 | 清华大学 | 载有外源配体分子的胞外体及其制备方法与应用 |
| US9085778B2 (en) | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
| BRPI0806436A2 (pt) | 2007-01-26 | 2011-09-06 | Univ Lousville Res Foundation Inc | modificação de componentes exossomais para uso como uma vacina |
| ES2749393T3 (es) | 2009-04-17 | 2020-03-20 | Univ Oxford Innovation Ltd | Composición para entrega de material genético |
| JP5667180B2 (ja) * | 2009-07-01 | 2015-02-12 | イオン メディックス インコーポレイテッド | 哺乳類の有核細胞に由来するマイクロベシクル及びその用途 |
| CN107412755A (zh) * | 2009-07-02 | 2017-12-01 | Ith免疫治疗控股公司 | 基于外泌体的癌症治疗 |
| ES2362589B1 (es) | 2009-12-28 | 2012-05-16 | Centre De Recerca En Salut Internacional De Barcelona | Exosomas derivados de reticulocitos infectados con plasmodium sp., método para su obtención y su uso. |
| ES2967272T3 (es) | 2011-11-30 | 2024-04-29 | Bullerdiek Joern | Expresión de miARNs en tejido placentario |
| GB201121070D0 (en) * | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
| EP3052616A4 (en) * | 2013-10-02 | 2017-03-29 | Paradigm Biopharmaceuticals Limited | A method of producing exosomes |
| EP2862874B1 (en) * | 2013-10-15 | 2018-12-12 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for producing polyclonal antibodies using an antigenic composition comprising protein-containing membrane vesicles |
| DE102014113688A1 (de) * | 2014-09-22 | 2016-03-24 | Jacobs University Bremen Ggmbh | Antigenspezifische immunfärbung von t-zellen |
| US20180042847A1 (en) * | 2015-03-16 | 2018-02-15 | Duncan ROSS | Method of treatment comprising membrane-enclosed vesicle |
| MX2017015279A (es) * | 2015-06-03 | 2018-05-15 | Innovex Therapeutics S L | Exasomas y su uso como vacunas. |
| AU2016275046B2 (en) | 2015-06-10 | 2022-07-28 | Board Of Regents, The University Of Texas System | Use of exosomes for the treatment of disease |
| CA3013685A1 (en) | 2016-03-03 | 2017-09-08 | Institut Gustave Roussy | Ptps-based vaccines against cancer |
| US20190112351A1 (en) * | 2016-04-04 | 2019-04-18 | National Institutes Of Biomedical Innovation, Health And Nutrition | Exosome-targeted dna vaccine |
| GB201717446D0 (en) | 2017-10-24 | 2017-12-06 | Evox Therapeutics Ltd | Affinity purification of engineering extracellular vesicles |
| WO2020231700A1 (en) * | 2019-05-11 | 2020-11-19 | Youngsuk Yi | Neurotoxin compositions and methods |
| CN110938670B (zh) * | 2019-11-07 | 2023-11-07 | 南方医科大学南方医院 | 微生物菌液与血清囊泡反应在检测微生物感染中的应用 |
| US20230143831A1 (en) * | 2020-02-28 | 2023-05-11 | National University Corporation Kanazawa University | Antigen-presenting extracellular vesicles, composition containing same, and method for production thereof |
| JP2021000093A (ja) * | 2020-08-05 | 2021-01-07 | 国立研究開発法人医薬基盤・健康・栄養研究所 | エキソソーム標的ｄｎａワクチン |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997005900A1 (en) * | 1995-08-03 | 1997-02-20 | Rijksuniversiteit Te Leiden | Cell derived antigen presenting vesicles |
-
1998
- 1998-11-05 FR FR9813946A patent/FR2785543B1/fr not_active Expired - Fee Related
-
1999
- 1999-11-04 EA EA200100509A patent/EA004428B1/ru not_active IP Right Cessation
- 1999-11-04 EP EP99954055A patent/EP1127110A1/fr not_active Withdrawn
- 1999-11-04 JP JP2000581168A patent/JP2002529074A/ja active Pending
- 1999-11-04 IL IL14263499A patent/IL142634A0/xx unknown
- 1999-11-04 WO PCT/FR1999/002691 patent/WO2000028001A1/fr not_active Application Discontinuation
- 1999-11-04 AU AU10514/00A patent/AU772451B2/en not_active Ceased
- 1999-11-04 CN CN99812879A patent/CN1325441A/zh active Pending
- 1999-11-04 CA CA002349679A patent/CA2349679A1/fr not_active Abandoned
- 1999-12-16 TW TW088119348A patent/TWI224138B/zh not_active IP Right Cessation
-
2004
- 2004-07-29 AU AU2004203482A patent/AU2004203482A1/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997005900A1 (en) * | 1995-08-03 | 1997-02-20 | Rijksuniversiteit Te Leiden | Cell derived antigen presenting vesicles |
Non-Patent Citations (2)
| Title |
|---|
| RAPOSO G ET AL (1997) MOL. BIOL. OF THE CELL 8:2631-45 * |
| ZITVOGEL L ET AL (1998) NATURE MEDICINE 4:594-600 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU1051400A (en) | 2000-05-29 |
| AU2004203482A1 (en) | 2004-08-26 |
| TWI224138B (en) | 2004-11-21 |
| EA200100509A1 (ru) | 2001-12-24 |
| CN1325441A (zh) | 2001-12-05 |
| EP1127110A1 (fr) | 2001-08-29 |
| CA2349679A1 (fr) | 2000-05-18 |
| FR2785543A1 (fr) | 2000-05-12 |
| WO2000028001A1 (fr) | 2000-05-18 |
| FR2785543B1 (fr) | 2003-02-28 |
| IL142634A0 (en) | 2002-03-10 |
| EA004428B1 (ru) | 2004-04-29 |
| JP2002529074A (ja) | 2002-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU772451B2 (en) | Modified exosomes and uses | |
| US10526407B2 (en) | T cell receptors and immune therapy using the same | |
| Panté et al. | Interactions and three-dimensional localization of a group of nuclear pore complex proteins. | |
| EP2016102B1 (en) | Chimeric t cell receptors and related materials and methods of use | |
| CA2081028C (en) | Cd2 binding domain of lymphocyte function associated antigen 3 | |
| US20200385468A1 (en) | Novel t cell receptors and immune therapy using the same | |
| Rombout et al. | Indications for a distinct putative T cell population in mucosal tissue of carp (Cyprinus carpio L.) | |
| JPH09502096A (ja) | 抗ｇｐ３９抗体およびその用途 | |
| JP2002186486A (ja) | Ｂ細胞上のｃｄ２８レセプターに対するリガンドおよび該リガンドを用いた細胞間相互作用の調節方法 | |
| AU2010228108A1 (en) | Compounds and methods for modulating an immune response | |
| De Bruijn et al. | Mechanisms of induction of primary virus‐specific cytotoxic T lymphocyte responses | |
| CN110272482B (zh) | 识别prame抗原短肽的t细胞受体 | |
| AU673985B2 (en) | CD8 binding domain peptides | |
| AU751151B2 (en) | T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof | |
| Matsuoka et al. | A novel type of cell death of lymphocytes induced by a monoclonal antibody without participation of complement. | |
| EP3354658A1 (en) | Novel t cell receptors and immune therapy using the same for the treatment of cancer and infectious diseases | |
| Taylor et al. | Differential expression of bovine MHC class II antigens identified by monoclonal antibodies | |
| AU7792691A (en) | Synthetic poly-ig receptor, receptor-antibody complexes, production and use thereof | |
| EP0503646A1 (en) | Monoclonal antibodies recognizing lymphocyte function associated antigen-3 | |
| EP2303407A1 (en) | Methods of detecting cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells | |
| Carini et al. | Formation of IgE-binding factors by T cells of patients infected with human immunodeficiency virus type 1. | |
| Kane et al. | Class I alloantigen is sufficient for cytolytic T lymphocyte binding and transmembrane signaling | |
| Andersson et al. | Surface glycoproteins of resting and activated human T lymphocytes | |
| Jardieu et al. | Relationship among IgE-binding factors with various molecular weights. | |
| Jui-Han et al. | Alloantigenic recognition of artificial glycosyl phosphatidylinositol-anchored HLA-A2. 1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |